Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Is cancer immunotherapy a private affair?: Immune checkpoint blockade, a relatively new cancer treatment, substantially extends the survival of a subset of patients. Previous work has shown that patients whose tumors harbor the largest number of mutations—and thus produce a large number of “neoantigens” recognized as foreign by the immune system—are most likely to benefit. Expanding on these earlier studies, Van Allen et al. studied over 100 patients with melanoma and found a similar correlation (see the Perspective by Gubin and Schreiber). There was no evidence, however, that specific neoantigen sequences were shared by patients who responded. Science , this issue p. 207 , see also p. 158
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ORR and Kaplan-Meier survival analysis revealed that the PathTIGR model effectively stratified patients with melanoma into subgroups exhibiting significantly disparate therapeutic responses (Fisher’s exact test, P < 0.0001; Fig. 4C) and clinical outcomes (log-rank test, P < 0.0001; Fig. 4, D and E).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“ORR and Kaplan-Meier survival analysis revealed that the PathTIGR model effectively stratified patients with melanoma into subgroups exhibiting significantly disparate therapeutic responses (Fisher’s exact test, P < 0.0001; Fig. 4C) and clinical outcomes (log-rank test, P < 0.0001; Fig. 4, D and E).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“The model achieved AUCs of 0.734, 0.729, and 0.935 at 1, 2, and 3 years, respectively (Fig. 4F).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“Cox proportional hazard regression analysis established the algorithm’s independence as a prognostic determinant following adjustment for conventional clinicopathological covariates (P < 0.001; Fig. 4G and table S1).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“it achieved an AUC of 0.989, an AUPRC of 0.993, an F1 score of 0.99, and a C-index of 0.989 (Fig. 4, A and B, and fig. S2A).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 2×
“To stratify our cohort, “clinical benefit” was defined using a composite end point of complete response or partial response to ipilimumab by RECIST criteria (21) or stable disease by RECIST criteria with overall survival greater than 1 year (n = 27).”
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981 · cited 1×
“We performed somatic mutation identification (table S1) and germline human lymphocyte antigen (HLA) typing (table S2) using established methods (14, 19).”
Self-citationThe future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · cited 1×
“Incorporation of patient-matched RNA-level information may help prioritize putative neoantigens and elucidate possible tumor immune microenvironmental effects, including interferon-related genes and additional immune checkpoint molecules that are relevant in melanoma (28).”
Cited by
Items 301–400 of 1,010
Precision Oncology: The Road Ahead
Senft, D., Leiserson, M. D. M., Ruppin, E., & Ronai, Z. A. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.08.003 · Cited by 195
“Furthermore, the expression of immune checkpoint regulators have correlated with increased patient survival [76].”
BackgroundInfluentialClinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy
Cabel, L., Proudhon, C., Romano, E., Girard, N., Lantz, O., Stern, M.-H., Pierga, J.-Y., & Bidard, F.-C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0074-3 · Cited by 196
Park, Y.-J., Kuen, D.-S., & Chung, Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0130-1 · Cited by 194
Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy
Li, J., Wang, W., Zhang, Y., Cieślik, M., Guo, J., Tan, M., Green, M. D., Wang, W., Lin, H., Li, W., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134402 · Cited by 191
“We found a nearly 3-fold decrease in the clinical response rate of melanoma patients with ARID1A C-terminal mutations as compared to patients without C-terminal mutations (31, 41-43) (Figure 7E).”
BackgroundGettinger, S. N., Choi, J., Mani, N., Sanmamed, M. F., Datar, I., Sowell, R., Du, V. Y., Kaftan, E., Goldberg, S., Dong, W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05032-8 · Cited by 191
Correlate tumor mutation burden with immune signatures in human cancers
Wang, X., & Li, M. (2019) · BMC Immunology · doi:10.1186/s12865-018-0285-5 · Cited by 191
Immunogenomic Landscape of Hematological Malignancies
Dufva, O., Pölönen, P., Brück, O., Keränen, M. A. I., Klievink, J., Mehtonen, J., Huuhtanen, J., Kumar, A., Malani, D., Siitonen, S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.002 · Cited by 190
Ravi, A., Hellmann, M. D., Arniella, M. B., Holton, M., Freeman, S. S., Naranbhai, V., Stewart, C., Leshchiner, I., Kim, J., Akiyama, Y., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01355-5 · Cited by 188
An, X., Zhu, Y., Zheng, T., Wang, G., Zhang, M., Li, J., Ji, H., Li, S., Yang, S., Xu, D., et al. (2019) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.11.003 · Cited by 188
“(B) The high expression of TMEM173 predicts a favorable prognosis of metastatic melanoma patients treated with monoclonal antibody against CTLA-4.”
MethodInfluentialHendrickx, W., Simeone, I., Anjum, S., Mokrab, Y., Bertucci, F., Finetti, P., Curigliano, G., Seliger, B., Cerulo, L., Tomei, S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1253654 · Cited by 185
“The increased responsiveness to immunotherapy of hyper mutated tumors has been attributed to enrichment in mutated antigens (neoantigens) that could be recognized by T cells.(25,54,55) According to such model, antitumor immune responses directed against neoantigens and counteracted by immune regulatory mechanisms migh…”
BackgroundBiomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
Nakamura, Y. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00119 · Cited by 185
“Overall, multiple studies have shown that a highmutation burden was associated with a better response to ICIs (51, 52).”
BackgroundIntratumoral Immunotherapy for Early-stage Solid Tumors
Hong, W. X., Haebe, S., Lee, A. S., Westphalen, C. B., Norton, J. A., Jiang, W., & Levy, R. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3642 · Cited by 183
Barroso-Sousa, R., Keenan, T. E., Pernas, S., Exman, P., Jain, E., Garrido-Castro, A. C., Hughes, M., Bychkovsky, B., Umeton, R., Files, J. L., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3507 · Cited by 182
The function and dysfunction of memory CD 8+ T cells in tumor immunity
Reading, J. L., Gálvez‐Cancino, F., Swanton, C., Lladser, A., Peggs, K. S., & Quezada, S. A. (2018) · Immunological Reviews · doi:10.1111/imr.12657 · Cited by 180
Melanoma: What do all the mutations mean?
Davis, E. J., Johnson, D. B., Sosman, J. A., & Chandra, S. (2018) · Cancer · doi:10.1002/cncr.31345 · Cited by 180
“A subsequent large sequencing study failed to replicate the tetrapeptide signature associations, although it redemonstrated strong associations between ipilimumab benefit and high mutation burdens.(25) Anti-PD-1 benefit in patients with melanoma also has been linked with high mutation burdens.”
ResultMartens, A., Wistuba-Hamprecht, K., Yuan, J., Postow, M. A., Wong, P., Capone, M., Madonna, G., Khammari, A., Schilling, B., Sucker, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0249 · Cited by 180
“We did not investigate which antigens are targeted by T cells, but increasing evidence indicates that the T-cell response targeting nonsynonymous individual tumor mutations is decisive for clinical responses on ipilimumab treatment (44, 45).”
BackgroundSelf-citationChen, H., Chong, W., Wu, Q., Yao, Y., Mao, M., & Wang, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01113 · Cited by 180
“It is also reported that neoantigen burden have a correlation with tumor mutation burden (5, 8).”
BackgroundThe impact of tumor profiling approaches and genomic data strategies for cancer precision medicine
Garofalo, A., Sholl, L., Reardon, B., Taylor-Weiner, A., Amin-Mansour, A., Miao, D., Liu, D., Oliver, N., MacConaill, L., Ducar, M., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0333-9 · Cited by 179
Self-citationGenomic Approaches to Understanding Response and Resistance to Immunotherapy
Braun, D. A., Burke, K. P., & Van Allen, E. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0066 · Cited by 179
“Indeed, the presence of this cytolytic activity signature was significantly associated with response to CTLA-4 blockade in metastatic melanoma (22).”
BackgroundInfluentialKabacaoglu, D., Ciecielski, K. J., Ruess, D. A., & Algül, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01878 · Cited by 179
Germline genetic contribution to the immune landscape of cancer
Sayaman, R. W., Saad, M., Thorsson, V., Hu, D., Hendrickx, W., Roelands, J., Porta-Pardo, E., Mokrab, Y., Farshidfar, F., Kirchhoff, T., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.011 · Cited by 179
Okuma, Y., Hosomi, Y., Nakahara, Y., Watanabe, K., Sagawa, Y., & Homma, S. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2016.11.023 · Cited by 176
Dendritic cell maturation in cancer
Moon, C. Y., Belabed, M., Park, M. D., Mattiuz, R., Puleston, D., & Merad, M. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-024-00787-3 · Cited by 170
Development of immune checkpoint therapy for cancer
Fritz, J. M., & Lenardo, M. J. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20182395 · Cited by 175
The role of neoantigens in response to immune checkpoint blockade
Riaz, N., Morris, L., Havel, J. J., Makarov, V., Desrichard, A., & Chan, T. A. (2016) · International Immunology · doi:10.1093/intimm/dxw019 · Cited by 175
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade
Shukla, S. A., Bachireddy, P., Schilling, B., Galonska, C., Zhan, Q., Bango, C., Langer, R., Lee, P. C., Gusenleitner, D., Keskin, D. B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.026 · Cited by 172
“Bottom: Boxplots depicting the individual RNA-seq expression value for each MAGEA and CSAG gene within this locus in the discovery cohort stratified by CB and NB status (Van Allen et al., 2015).”
BackgroundMethodInfluentialSelf-citationMei, S., Li, F., Leier, A., Marquez-Lago, T. T., Giam, K., Croft, N. P., Akutsu, T., Smith, A. I., Li, J., Rossjohn, J., et al. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbz051 · Cited by 173
“Equally, several studies have found that neo-antigens generated as a result of non-synonymous mutations in cancer cells play a significant role in the dynamics of the anti-tumour immune response [6–9].”
BackgroundKinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
Brea, E. J., Oh, C. Y., Manchado, E., Budhu, S., Gejman, R. S., Mo, G., Mondello, P., Han, J. E., Jarvis, C. A., Ulmert, D., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0177 · Cited by 173
The genomic landscape of cutaneous melanoma
Zhang, T., Dutton‐Regester, K., Brown, K. M., & Hayward, N. K. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12459 · Cited by 172
“High somatic mutation burden in melanoma has already been linked to favorable outcomes of immune-based therapeutic approaches using CTLA-4 antibodies (Snyder et al., 2014; Van Allen et al., 2015).”
BackgroundPredicting Antigen Presentation—What Could We Learn From a Million Peptides?
Gfeller, D., & Bassani-Sternberg, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01716 · Cited by 170
Komdeur, F. L., Prins, T. M., van de Wall, S., Plat, A., Wisman, G. B. A., Hollema, H., Daemen, T., Church, D. N., de Bruyn, M., & Nijman, H. W. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1338230 · Cited by 168
“In these malignancies, responses to immune checkpoint inhibitors have been strongly linked to the presence of neo-antigens in cancer cells (particularly those expressed across lesions) that provide a true tumor-specific target for T cells for which tolerance has likely not been established.(38,39) In cervical cancer,…”
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab
Costantini, A., Julie, C., Dumenil, C., Hélias-Rodzewicz, Z., Tisserand, J., Dumoulin, J., Giraud, V., Labrune, S., Chinet, T., Emile, J.-F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1452581 · Cited by 168
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
Anagnostou, V., Yarchoan, M., Hansen, A. R., Wang, H., Verde, F., Sharon, E., Collyar, D., Chow, L. Q. M., & Forde, P. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3065 · Cited by 166
Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
Mushtaq, M. U., Papadas, A., Pagenkopf, A., Flietner, E., Morrow, Z., Chaudhary, S. G., & Asimakopoulos, F. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0376-0 · Cited by 165
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Conway, J. R., Kofman, E., Mo, S. S., Elmarakeby, H., & Van Allen, E. (2018) · Genome Medicine · doi:10.1186/s13073-018-0605-7 · Cited by 165
Choucair, K., Morand, S., Stanbery, L., Edelman, G., Dworkin, L., & Nemunaitis, J. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0174-y · Cited by 164
“In fact, several studies have demonstrated an association between high TMB and response to anti-CTLA4 or anti-PD-1 [8, 48, 49].”
BackgroundNewell, F., Pires da Silva, I., Johansson, P. A., Menzies, A. M., Wilmott, J. S., Addala, V., Carlino, M. S., Rizos, H., Nones, K., Edwards, J. J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2021.11.012 · Cited by 164
Self-citationBiomarkers associated with checkpoint inhibitors
Manson, G., Norwood, J., Marabelle, A., Kohrt, H., & Houot, R. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw181 · Cited by 164
The Relationship Between Dormant Cancer Cells and Their Microenvironment
(2016) · Advances in Cancer Research · doi:10.1016/bs.acr.2016.07.002 · Cited by 162
“A recent study has shown that the total load of nonsynonymous mutations seems to correlate with a patient’s response to CTLA4 therapy (Van Allen et al., 2015).”
BackgroundJohnson, D. B., Nixon, M. J., Wang, Y., Wang, D. Y., Castellanos, E., Estrada, M. V., Ericsson-Gonzalez, P. I., Cote, C. H., Salgado, R., Sanchez, V., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120360 · Cited by 163
Melaiu, O., Chierici, M., Lucarini, V., Jurman, G., Conti, L. A., De Vito, R., Boldrini, R., Cifaldi, L., Castellano, A., Furlanello, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19781-y · Cited by 163
Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different
Lee, C.-H., Yelensky, R., Jooss, K., & Chan, T. A. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.04.005 · Cited by 162
Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state
Cerezo-Wallis, D., Contreras-Alcalde, M., Troulé, K., Catena, X., Mucientes, C., Calvo, T. G., Cañón, E., Tejedo, C., Pennacchi, P. C., Hogan, S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1073-3 · Cited by 162
Danilova, L., Wang, H., Sunshine, J., Kaunitz, G. J., Cottrell, T. R., Xu, H., Esandrio, J., Anders, R. A., Cope, L., Pardoll, D. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607836113 · Cited by 161
Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance
Lin, H., Kryczek, I., Li, S., Green, M. D., Ali, A., Hamasha, R., Wei, S., Vatan, L., Szeliga, W., Grove, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.023 · Cited by 159
Advances in immunotherapy for melanoma
Redman, J. M., Gibney, G. T., & Atkins, M. B. (2016) · BMC Medicine · doi:10.1186/s12916-016-0571-0 · Cited by 160
“published [81], where tumor samples of 110 melanoma patients treated with ipilimumab were analyzed via whole exome sequencing.”
MethodApplications of single-cell and bulk RNA sequencing in onco-immunology
Kuksin, M., Morel, D., Aglave, M., Danlos, F., Marabelle, A., Zinovyev, A. Y., Gautheret, D., & Verlingue, L. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.005 · Cited by 207
Optimizing panel-based tumor mutational burden (TMB) measurement
Budczies, J., Allgäuer, M., Litchfield, K., Rempel, E., Christopoulos, P., Kazdal, D., Endris, V., Thomas, M., Fröhling, S., Peters, S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz205 · Cited by 159
“This paradigm is supported by accumulating evidence that tumors with higher TMB are more likely to respond to ICB in various settings including PD-(L)1 blockade in non-small-cell lung cancer (NSCLC) [9] and urothelial carcinoma [10], CTLA-4 blockade in malignant melanoma [11, 12] and combined PD(L)-1 and CTLA-4 blocka…”
MethodSubudhi, S. K., Vence, L., Zhao, H., Blando, J., Yadav, S. S., Xiong, Q., Reuben, A., Aparicio, A., Corn, P. G., Chapin, B. F., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz3577 · Cited by 158
“Some of the highest objective response rates to ICB are observed in patients with melanoma and non–small cell lung cancer (NSCLC), tumors that have high tumor mutational burden (TMB) and neoantigen frequency (1), both of which have been associated with clinical responses to ICB (2–5).”
BackgroundInfluentialSelf-citationIntrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy
Zhao, X., & Subramanian, S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2379 · Cited by 157
“For example, in genome-wide studies of non–small cell lung cancer (NSCLC) andmelanoma (the two cancers that have so far demonstrated the best response to ICBT), the mutation burden and the neoantigen load closely correlated with a better clinical outcome (11, 12).”
BackgroundKim, S., Kim, H. S., Kim, E., Lee, M. G., Shin, E.-C., Paik, S., & Kim, S. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy022 · Cited by 158
“Although the number of neopeptides generated by somatic mutation seemed to be important for predicting antitumor activity of immunotherapy, the criteria to identify neopeptides and the correlation were inconsistent across studies [3, 18].”
BackgroundResultTitin mutation associated with responsiveness to checkpoint blockades in solid tumors
Jia, Q., Wang, J., He, N., He, J., & Zhu, B. (2019) · JCI Insight · doi:10.1172/jci.insight.127901 · Cited by 158
De Mattos-Arruda, L., Vazquez, M., Finotello, F., Lepore, R., Porta, E., Hundal, J., Amengual-Rigo, P., Ng, C. K. Y., Valencia, A., Carrillo, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.008 · Cited by 157
Synthetic lethality-mediated precision oncology via the tumor transcriptome
Lee, J. S., Nair, N. U., Dinstag, G., Chapman, L., Chung, Y., Wang, K., Sinha, S., Cha, H., Kim, D., Schperberg, A. V., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.030 · Cited by 158
Kirilovsky, A., Marliot, F., El Sissy, C., Haicheur, N., Galon, J., & Pagès, F. (2016) · International Immunology · doi:10.1093/intimm/dxw021 · Cited by 157
T-cell receptor-engineered T cells for cancer treatment: current status and future directions
Ping, Y., Liu, C., & Zhang, Y. (2018) · Protein & Cell · doi:10.1007/s13238-016-0367-1 · Cited by 157
“These antigens can induce an immune responses and are promising candidate targets for use in vaccination or T cell therapy, such as melanoma-associated antigen (MAGE)-A3 (Zhang et al., 2003), MAGE-A4 (Zhang et al., 2002), and New York esophageal squamous cell carcinoma (NY-ESO)-1 (van der Bruggen et al., 1994; Valmori…”
BackgroundBobisse, S., Genolet, R., Roberti, A., Tanyi, J. L., Racle, J., Stevenson, B. J., Iseli, C., Michel, A., Le Bitoux, M.-A., Guillaume, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03301-0 · Cited by 157
Kim, J. Y., Kronbichler, A., Eisenhut, M., Hong, S. H., van der Vliet, H. J., Kang, J., Shin, J. I., & Gamerith, G. (2019) · Cancers · doi:10.3390/cancers11111798 · Cited by 165
“2015 [21] Retrospective cohort Melanoma Ipilimumab Tumor WES ≥202 (median) 197 (7–5854) 110 (55/55) OS, PFS”
BackgroundInfluentialUpdate on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)
Saltos, A. N., Shafique, M. R., & Chiappori, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01074 · Cited by 175
“This predictive potential was first shown in metastatic melanoma (17) and NSCLC (18, 19) but it was also suggested in SCLC where a survival analysis by TMB from CheckMate 032 showed a benefit for those patients in the highest TMB tercile (20).”
ResultLi, G., Choi, J. E., Kryczek, I., Sun, Y., Liao, P., Li, S., Wei, S., Grove, S., Vatan, L., Nelson, R., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.12.008 · Cited by 168
Shao, C., Li, G., Huang, L., Pruitt, S., Castellanos, E., Frampton, G., Carson, K. R., Snow, T., Singal, G., Fabrizio, D., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.25109 · Cited by 155
Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment
Varn, F. S., Wang, Y., Mullins, D. W., Fiering, S., & Cheng, C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2490 · Cited by 153
Tailoring inorganic nanoadjuvants towards next-generation vaccines
Li, X., Wang, X., & Ito, A. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00028j · Cited by 156
Size matters: Dissecting key parameters for panel‐based tumor mutational burden analysis
Buchhalter, I., Rempel, E., Endris, V., Allgäuer, M., Neumann, O., Volckmar, A., Kirchner, M., Leichsenring, J., Lier, A., von Winterfeld, M., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.31878 · Cited by 154
Dietary Lactobacillus -Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy
Kawanabe-Matsuda, H., Takeda, K., Nakamura, M., Makino, S., Karasaki, T., Kakimi, K., Nishimukai, M., Ohno, T., Omi, J., Kano, K., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0929 · Cited by 150
Rodrigues, M. J., Mobuchon, L., Houy, A., Fiévet, A., Gardrat, S., Barnhill, R. L., Popova, T. G., Servois, V., Rampanou, A., Mouton, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04322-5 · Cited by 152
Richman, L. P., Vonderheide, R. H., & Rech, A. J. (2019) · Cell Systems · doi:10.1016/j.cels.2019.08.009 · Cited by 152
Kalaora, S., Lee, J. S., Barnea, E., Levy, R., Greenberg, P., Alon, M., Yagel, G., Eli, G. B., Oren, R., Peri, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14639-9 · Cited by 166
CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer
Lin, A., Qi, C., Wei, T., Li, M., Cheng, Q., Liu, Z., Luo, P., & Zhang, J. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac129 · Cited by 152
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer
Liu, D., Abbosh, P., Keliher, D., Reardon, B., Miao, D., Mouw, K., Weiner-Taylor, A., Wankowicz, S., Han, G., Teo, M. Y., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02320-7 · Cited by 151
Self-citationColorectal cancer immunotherapy-Recent progress and future directions
Zhao, W., Jin, L., Chen, P., Li, D., Gao, W., & Dong, G. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215816 · Cited by 164
Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy
Riaz, N., Havel, J. J., Kendall, S. M., Makarov, V., Walsh, L. A., Desrichard, A., Weinhold, N., & Chan, T. A. (2016) · Nature Genetics · doi:10.1038/ng.3677 · Cited by 150
Zhu, J., Armstrong, A. J., Friedlander, T. W., Kim, W. K., Pal, S. K., George, D. J., & Zhang, T. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0314-1 · Cited by 166
“Tumor mutational burden and MSI status It has been observed that tumors with a higher mutational burden may have a better response to immunotherapy [34].”
BackgroundImmune and molecular correlates in melanoma treated with immune checkpoint blockade
Byrne, E. H., & Fisher, D. E. (2017) · Cancer · doi:10.1002/cncr.30444 · Cited by 149
“although the load of potentially immunogenic neoantigens was correlated with response to anti-CTLA4, there were no clear patterns of repeated neoantigens across responders that distinguished them from nonresponders.(28) Taken together, the correlation between mutational load and response to checkpoint blockade is fair…”
BackgroundResultInfluentialZhu, G., Su, H., Johnson, C. H., Khan, S. A., Kluger, H., & Lu, L. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.053 · Cited by 148
The role of immune checkpoint inhibition in the treatment of ovarian cancer
Gaillard, S. L., Secord, A. A., & Monk, B. J. (2016) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-016-0033-6 · Cited by 165
“In fact, there have been patients who achieve long-term survival benefit without evidence of clinical response [53].”
BackgroundPredicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Morrison, C., Pabla, S., Conroy, J. M., Nesline, M. K., Glenn, S. T., Dressman, D., Papanicolau-Sengos, A., Burgher, B., Andreas, J., Giamo, V., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0344-8 · Cited by 147
“A high mutational burden [3, 21], more than 7.”
BackgroundCharacterizing the ecological and evolutionary dynamics of cancer
Zahir, N., Sun, R., Gallahan, D., Gatenby, R. A., & Curtis, C. N. (2020) · Nature Genetics · doi:10.1038/s41588-020-0668-4 · Cited by 153
Muzaffar, J., Bari, S., Kirtane, K., & Chung, C. H. (2021) · Cancers · doi:10.3390/cancers13020338 · Cited by 163
“Increased TMB has been related to improved response to immunotherapy in non-small cell lung cancer (NSCLC) [88] and clinical response and OS in melanoma [89].”
BackgroundMiller, A., Asmann, Y., Cattaneo, L., Braggio, E., Keats, J., Auclair, D., Lonial, S., The MMRF CoMMpass Network, Russell, S. J., & Stewart, A. K. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.94 · Cited by 145
Challenges in neoantigen-directed therapeutics
Lybaert, L., Lefever, S., Fant, B., Smits, E., De Geest, B., Breckpot, K., Dirix, L., Feldman, S. A., van Criekinge, W., Thielemans, K., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.10.013 · Cited by 142
Molecular Diagnostics in Clinical Oncology
Соколенко, А. П., & Имянитов, Е. Н. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00076 · Cited by 166
“…tests, the determination of tumor mutation burden in, e.g., lung cancers or melanomas, is more complicated: it is based on the whole exome sequencing, deals with continuous variable and does not have yet established thresholds for clinical decisions (Rizvi et al., 2015; Van Allen et al., 2015).”
BackgroundFerroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes
Bebber, C. M., Thomas, E. S., Stroh, J., Chen, Z., Androulidaki, A., Schmitt, A., Höhne, M. N., Stüker, L., Alves, C. D. P., Khonsari, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22336-4 · Cited by 151
“SCLC is amongst the deadliest human cancers with a characteristically high TMB (4), a feature known to positively correlate with response to immunotherapy (7, 56).”
Nguyen, L. T., Saibil, S. D., Sotov, V., Le, M. X., Khoja, L., Ghazarian, D., Bonilla, L., Majeed, H., Hogg, D., Joshua, A. M., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02307-x · Cited by 143
Shim, J. H., Kim, H. S., Cha, H., Kim, S., Kim, T. M., Anagnostou, V., Choi, Y.-L., Jung, H. A., Sun, J.-M., Ahn, J. S., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.004 · Cited by 143
Zhang, C., Li, Z., Qi, F., Hu, X., & Luo, J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.10.84 · Cited by 165
“For example, great efforts have been made in immune checkpoint blockade (ICB) for various malignancies, such as lung cancer (10,11), breast cancer (12,13) and melanoma (14), and the chimeric antigen receptor T cell therapy is being clinical used for leukemia and lymphoma treatment (15).”
BackgroundZhang, N., Zhang, H., Wu, W., Zhou, R., Li, S., Wang, Z., Dai, Z., Zhang, L., Liu, F., Liu, Z., et al. (2022) · Theranostics · doi:10.7150/thno.74281 · Cited by 140
“The GSE35640 (melanoma) [27], GSE91061 (melanoma) [28], GSE78220 (melanoma) [29], Allen (melanoma) [30], Nathanson (melanoma) [31], IMvigor (urothelial carcinoma) [32], Braun (renal cell carcinoma) [33], GSE179351 (colorectal adenocarcinoma and pancreatic adenocarcinoma) [34], GSE165252 (esophageal adenocarcinoma) [35…”
MethodTargeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines
Türeci, Ö., Vormehr, M., Diken, M., Kreiter, S., Huber, C., & Sahin, U. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1509 · Cited by 141
“Snyder and colleagues proposed that anti–CTLA-4 checkpoint blockade favors T-cell responses against neoantigens sharing common peptide substring patterns (22); however, this finding could not be confirmed in a study by Van Allen and colleagues investigating responses in a larger cohort of cancer patients (18).”
ResultDrug discovery in advanced prostate cancer: translating biology into therapy
Yap, T. A., Smith, A. D., Ferraldeschi, R., Al‐Lazikani, B., Workman, P., & Bono, J. S. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.120 · Cited by 157
The genetics of uveal melanoma: current insights
Höiom, V., & Helgadóttir, H. (2016) · The Application of Clinical Genetics · doi:10.2147/tacg.s69210 · Cited by 153
Rodriguez, G., Galpin, K., McCloskey, C., & Vanderhyden, B. (2018) · Cancers · doi:10.3390/cancers10080242 · Cited by 140
Wang, G., Chow, R. D.-W., Zhu, L., Bai, Z., Ye, L., Zhang, F., Renauer, P. A., Dong, M. B., Dai, X., Zhang, X., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1448 · Cited by 148
“These include whole-genome sequencing (7, 9, 10), proteomic analysis (11), single-cell transcriptomic analysis (12), in vitro cancer–immune cell cocultures (13, 14), and ex vivo/in vivo screens using cell lines in tumor transplant models (15).”
BackgroundIdentification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia
Malaker, S. A., Penny, S. A., Steadman, L. G., Myers, P. T., Loke, J. C., Raghavan, M., Bai, D. L., Shabanowitz, J., Hunt, D. F., & Cobbold, M. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0280 · Cited by 140
“In patients with cancers that have high mutational loads, such as non–small cell lung cancer and melanoma, CD8þ T cells can be identified within the tumor that are specific for MHC class I–restricted neoantigens in response to immunotherapy (10, 11).”
BackgroundGhorani, E., Rosenthal, R., McGranahan, N., Reading, J. L., Lynch, M., Peggs, K. S., Swanton, C., & Quezada, S. A. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx687 · Cited by 140
“Further datasets of immunotherapy-treated patients comprised a cohort with stage IV NSCLC of predominantly adenocarcinoma subtype treated with pembrolizumab [11] and two cohorts of patients with advanced melanoma treated with anti-CTLA-4 directed immunotherapies [9, 10].”
BackgroundMethodResultInfluentialIntegrated genomic analyses reveal frequent TERT aberrations in acral melanoma
Liang, W. S., Hendricks, W. P. D., Kiefer, J., Schmidt, J. E., Sekar, S., Carpten, J. D., Craig, D. W., Adkins, J. R., Cuyugan, L., Manojlovic, Z., et al. (2017) · Genome Research · doi:10.1101/gr.213348.116 · Cited by 154
“Neo-antigen burdenwas associated withmutation burden (0.89, Pearson’s correlation) as shown in studies of CM (Snyder et al. 2014; Van Allen et al. 2015; Hugo et al. 2016).”
BackgroundResultInfluentialZaitsev, A., Chelushkin, M., Dyikanov, D., Cheremushkin, I., Shpak, B., Nomie, K., Zyrin, V., Nuzhdina, E., Lozinsky, Y., Zotova, A., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.07.006 · Cited by 139
Biomarkers for Immunotherapy: Current Developments and Challenges
Spencer, K. R., Wang, J., Silk, A. W., Ganesan, S., Kaufman, H. L., & Mehnert, J. M. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_160766 · Cited by 160
Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies
Minchom, A. R., Aversa, C., & Lopez, J. S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918786658 · Cited by 151
Cao, D., Xu, H., Xu, X., Guo, T., & Ge, W. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1629258 · Cited by 155
Immune cell infiltration-based signature for prognosis and immunogenomic analysis in breast cancer
Wang, S., Zhang, Q., Yu, C., Cao, Y., Zuo, Y., & Yang, L. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa026 · Cited by 163
Metadata
- Authors
- Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., Utikal, J., Hassel, J. C., Weide, B., Kaehler, K. C., Loquai, C., Mohr, P., Gutzmer, R., Dummer, R., Gabriel, S., Wu, C. J., Schadendorf, D., & Garraway, L. A.
- Affiliations
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Broad Institute (US)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- The Netherlands Cancer Institute (NL)
- Department of Medical Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
- University Hospital Zurich (CH)
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- Universitätsklinikum Tübingen (DE)
- University Hospital Schleswig-Holstein (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Elbe Kliniken Stade-Buxtehude (DE)
- Medizinische Hochschule Hannover (DE)
- Corresponding author
- Miao, Diana
- Schilling, Bastian
- Schadendorf, Dirk
- Garraway, Levi A.
- ORCID
- Venue
- Science
- Published
- 2015-10-09
- Volume
- 350
- Issue
- 6257
- Pages
- 207-211
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC5054517
- OpenAlex
- W2107429737
- Cited by
- 2,839
- References
- 42
- Citations by year
- 2026: 106 · 2025: 187 · 2024: 236 · 2023: 308 · 2022: 313 · 2021: 348 · 2020: 327 · 2019: 274 · 2018: 270 · 2017: 248 · 2016: 207 · 2015: 12
- FWCI
- 107.45
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- NIH (U54 HG003067)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- metastatic melanoma, CTLA-4 blockade, ipilimumab, immune checkpoint inhibitors, tumor mutational burden, neoantigens, tumor microenvironment, predictive biomarkers, treatment response, exome sequencing, transcriptome, germline mutations
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antigens, Neoplasm, DNA Mutational Analysis, Female, HLA Antigens, Humans, Male, Melanoma, Middle Aged, Mutation, Skin Neoplasms, Cohort Studies, Drug Resistance, Neoplasm, Genomics, Biomarkers, Pharmacological, Young Adult, Tumor Microenvironment, Cell Cycle Checkpoints, Exome, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.